This study suggests bronchovascular structures and the esophagus may safely tolerate higher cumulative doses when ultracentral tumors are treated with combination of conventional fractionation and SBRT boost. Their proposed constraints, now under prospective evaluation, could help define just how far we could safely escalate dose in the mediastinum with mixed fractionation. | Gueiderikh, Adv Radiat Oncol 2025
